Results 11 to 20 of about 46,730 (243)

Phosphodiesterase type 5 inhibitors and erectile dysfunction

South African Family Practice, 2010
Erectile dysfunction (ED) affects millions of men globally and may adversely affect his, and potentially his partners’, quality of life. The introduction, a decade ago, of the phosphodiesterase type 5- (PDE5-) inhibitors has revolutionised the management
Catherine Whittaker
doaj   +1 more source

Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors

Pulmonary Circulation, 2020
Adherence to therapy for pulmonary arterial hypertension is essential to optimize patient outcomes, but data on real-world adherence to different pulmonary arterial hypertension drug classes are limited.
Robert P. Frantz, Jerrold W. Hill, Cassandra A. Lickert, Rolin L. Wade, Michele R. Cole, Yuen Tsang, William Drake   +6 more
doaj   +1 more source

Phosphodiesterase 5 inhibitors for pulmonary hypertension [PDF]

Cochrane Database of Systematic Reviews, 2017
Pulmonary hypertension (PH) comprises a group of complex and heterogenous conditions, characterised by elevated pulmonary artery pressure, and which left untreated leads to right-heart failure and death. PH includes World Health Organisation (WHO) Group 1 pulmonary arterial hypertension (PAH); Group 2 consists of PH due to left-heart disease (PH-LHD ...
Hayley, Barnes, Zoe, Brown, Andrew, Burns, Trevor, Williams   +3 more
openaire   +3 more sources

Phosphodiesterase Inhibitors: Present and Future

Barcelona Respiratory Network Reviews, 2023
Phosphodiesterase (PDE) inhibitors act on specific phosphodiesterase enzymes (fundamentally 3, 4 and 5), which are characterized by their expression in different organs.
José L. Izquierdo-Alonso
doaj   +1 more source

Cardiac Uses of Phosphodiesterase-5 Inhibitors

Journal of the American College of Cardiology, 2012
Phosphodiesterase-5 inhibitors (PDE5Is) improve erectile function by enhancing nitric oxide availability in the penis and its supplying vasculature, resulting in vasodilation and increased blood flow. PDE5Is might benefit cardiovascular diseases because phosphodiesterase-5 is also located elsewhere in the body, including the pulmonary and systemic ...
Schwartz, Bryan G., Levine, Laurence A., Comstock, Gary, Stecher, Vera J., Kloner, Robert A.   +4 more
openaire   +2 more sources

A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool

Journal of Research in Pharmacy Practice, 2015
Cyclic nucleotide phosphodiesterases (PDEs) are known as a super-family of enzymes which catalyze the metabolism of the intracellular cyclic nucleotides, cyclic-3',5'-adenosine monophosphate (cAMP), and cyclic-3',5'-guanosine monophosphate that are ...
Nahid Eskandari, Omid Mirmosayyeb, Gazaleh Bordbari, Reza Bastan, Zahra Yousefi, Alireza Andalib   +5 more
doaj   +1 more source

Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study

Pulmonary Circulation, 2020
Phosphodiesterase-5 inhibitors are commonly used in pulmonary arterial hypertension but, as suggested by the RESPITE study, phosphodiesterase-5 inhibitor therapy (mono-/combination) does not always have a satisfactory treatment effect.
Clara Hjalmarsson, Oisin Butler, Roger Hesselstrand, Katsiaryna Holl, Kjell Jansson, Rogier Klok, Göran Rådegran, Stefan Söderberg, Barbro Kjellström   +8 more
doaj   +1 more source

Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review

Journal of Ophthalmic & Vision Research, 2021
Phosphodiesterase type 5 inhibitors such as sildenafil citrate and tadalafil are well known for the treatment of erectile dysfunction. However, their use in the presence of pulmonary hypertension can cause ophthalmologic side effects, including non ...
Francisco Barroso, João Crispim Ribeiro, Eduardo P. Miranda   +2 more
doaj   +1 more source

Effect of phosphodiesterase-5 inhibitor on hearing

The Journal of Laryngology & Otology, 2009
AbstractObjective:Following a report of sudden hearing loss in a patient taking phosphodiesterase type 5 inhibitor, and a Food and Drug Administration announcement concerning this class of drugs, a study was planned to investigate if ototoxicity occurs in patients using phosphodiesterase 5 inhibitor for erectile dysfunction.Methods:Eighteen patients ...
Okuyucu, S., Guven, O. E., Akoglu, E., Ucar, E., Dagli, S.   +4 more
openaire   +2 more sources

Phenanthrenes from as Novel Phosphodiesterase-5 Inhibitors

Natural Product Communications, 2017
Phosphodiesterase 5 (PDE5) inhibitors can be used for the treatment of erectile dysfunction and pulmonary hypertension. In order to search for new leads of PDE5 inhibitors, we investigated the chemical constituents of the tubers of Eulophia macrobulbon ...
Prapapan Temkitthawon, Kanokwan Changwichit, Nantaka Khorana, Jarupa Viyoch, Khanit Suwanborirux, Kornkanok Ingkaninan   +5 more
doaj   +1 more source